{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:57:25Z","timestamp":1778644645613,"version":"3.51.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1016\/j.prrv.2007.04.009","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T11:11:59Z","timestamp":1181041919000},"page":"148-154","source":"Crossref","is-referenced-by-count":40,"title":["Childhood tuberculosis: old and new vaccines"],"prefix":"10.1016","volume":"8","author":[{"given":"Gregory","family":"Hussey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Hawkridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem","family":"Hanekom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prrv.2007.04.009_bib1","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/S0140-6736(02)09096-7","article-title":"Drug development for neglected diseases: a deficient market and a public-health policy failure","volume":"359","author":"Trouiller","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2007.04.009_bib2","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(06)68384-0","article-title":"The global epidemiology of tuberculosis","volume":"267","author":"Dye","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2007.04.009_bib3","unstructured":"World Health Organisation. WHO Declares TB an Emergency in Africa. http:\/\/www.who.int\/mediacentre\/news\/releases\/2005\/africa_emergency\/en\/index.html (accessed April 2, 2007)."},{"key":"10.1016\/j.prrv.2007.04.009_bib4","unstructured":"Fine PA, Carneiro IAM, Milstein J, Clements CJ. Issues Relating to the Use of BCG in Immunization Programmes: A Discussion Document. WHO\/V&B\/99.23. Geneva: WHO, 1999."},{"key":"10.1016\/j.prrv.2007.04.009_bib5","unstructured":"National Institutes of Health. Tuberculosis Vaccines: State of the Science. http:\/\/www.niaid.nih.gov\/dmid\/tuberculosis\/tbvaccine.htm (accessed April 4, 2007)."},{"key":"10.1016\/j.prrv.2007.04.009_bib6","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","article-title":"Comparative genomics of BCG vaccines by whole-genome DNA microarray","volume":"1284","author":"Behr","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.prrv.2007.04.009_bib7","unstructured":"World Health Organisation. BCG \u2013 the Current Vaccine for Tuberculosis. http:\/\/www.who.int\/vaccine_research\/diseases\/tb\/vaccine_development\/bcg\/en\/ (accessed April 4, 2007)."},{"key":"10.1016\/j.prrv.2007.04.009_bib8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.271.9.698","article-title":"Efficacy of BCG vaccine in the prevention of tuberculosis \u2013 meta-analysis of the published literature","volume":"271","author":"Colditz","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.prrv.2007.04.009_bib9","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/ije\/22.6.1154","article-title":"Protective effect of BCG against tuberculous meningitis and military tuberculosis: a meta-analysis","volume":"22","author":"Rodrigues","year":"1993","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.prrv.2007.04.009_bib10","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2007.04.009_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.321.7274.1435","article-title":"Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa","volume":"321","author":"Kristensen","year":"2000","journal-title":"Br Med J"},{"key":"10.1016\/j.prrv.2007.04.009_bib12","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","article-title":"Variation in protection by BCG: implications of and for heterologous immunity","volume":"346","author":"Fine","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2007.04.009_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1086\/322042","article-title":"Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in Northern Malawi","volume":"184","author":"Black","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.prrv.2007.04.009_bib14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/IAI.70.2.672-678.2002","article-title":"Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis","volume":"70","author":"Brandt","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.prrv.2007.04.009_bib15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2567.2002.01366.x","article-title":"Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies","volume":"105","author":"Hussey","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.prrv.2007.04.009_bib16","first-page":"25","article-title":"BCG vaccine","volume":"79","author":"World Health Organisation","year":"2004","journal-title":"Wkly Epidemiol Rep"},{"key":"10.1016\/j.prrv.2007.04.009_bib17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.vaccine.2006.07.020","article-title":"The risk of disseminated Bacille Calmette\u2013Guerin (BCG) disease in HIV-infected children","volume":"25","author":"Hesseling","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.prrv.2007.04.009_bib18","unstructured":"World Health Organization. Global Advisory Committee on Vaccine Safety, 29\u201330th November 2006. WER 2007; 82: 2\u20138."},{"key":"10.1016\/j.prrv.2007.04.009_bib19","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1086\/341901","article-title":"New vaccines for the prevention of tuberculosis","volume":"35","author":"Von Reyn","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.prrv.2007.04.009_bib20","first-page":"483","article-title":"What's new in tuberculosis vaccines","volume":"80","author":"Ginsberg","year":"2002","journal-title":"Bull WHO"},{"key":"10.1016\/j.prrv.2007.04.009_bib21","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1086\/344359","article-title":"Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity","volume":"186","author":"Hoft","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.prrv.2007.04.009_bib22","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.4049\/jimmunol.163.4.2249","article-title":"Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette\u2013Guerin vaccination","volume":"163","author":"Marchant","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.prrv.2007.04.009_bib23","doi-asserted-by":"crossref","unstructured":"Hanekom WA, The immune response to BCG vaccination of newborns. Ann N Y Acad Sci 2005; 1062: 69\u201378.","DOI":"10.1196\/annals.1358.010"},{"key":"10.1016\/j.prrv.2007.04.009_bib24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/499825","article-title":"The effect of bacille Calmette\u2013Guerin vaccine strain and route of administration on induced immune responses in vaccinated infants","volume":"193","author":"Davids","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.prrv.2007.04.009_bib25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1365-2249.2006.03222.x","article-title":"The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette\u2013Guerin vaccination in southern England and northern Malawi","volume":"146","author":"Weir","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.prrv.2007.04.009_bib26","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.4049\/jimmunol.165.12.7088","article-title":"Human CD8+ CTL specific for the mycobacterial major secreted antigen 85A","volume":"165","author":"Smith","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.prrv.2007.04.009_bib27","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.4049\/jimmunol.177.8.5647","article-title":"Bacillus Calmette Guerin vaccination of human newborns induces a specific, functional CD8+ T cell response","volume":"177","author":"Murray","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.prrv.2007.04.009_bib28","unstructured":"Hanekom WA. Unpublished observations, 2006."},{"key":"10.1016\/j.prrv.2007.04.009_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.tube.2004.08.001","article-title":"Mouse and guinea pig models for testing new tuberculosis vaccines","volume":"85","author":"Orme","year":"2005","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.prrv.2007.04.009_bib30","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.micinf.2005.10.033","article-title":"Lessons from experimental Mycobacterium tuberculosis infections","volume":"8","author":"Flynn","year":"2006","journal-title":"Microbes Infect"},{"key":"10.1016\/j.prrv.2007.04.009_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tube.2003.08.010","article-title":"Immunology of tuberculosis and implications in vaccine development","volume":"84","author":"Flynn","year":"2004","journal-title":"Tuberculosis (Edinb)"},{"issue":"Suppl 2","key":"10.1016\/j.prrv.2007.04.009_bib32","doi-asserted-by":"crossref","first-page":"ii50","DOI":"10.1136\/ard.2004.028258","article-title":"New issues in tuberculosis","volume":"63","author":"Kaufmann","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.prrv.2007.04.009_bib33","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/IAI.68.5.2948-2953.2000","article-title":"CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis","volume":"68","author":"Freidag","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.prrv.2007.04.009_bib34","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1016\/j.vaccine.2006.03.072","article-title":"Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31","volume":"24","author":"Agger","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.prrv.2007.04.009_bib35","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1128\/IAI.71.6.3146-3154.2003","article-title":"The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection","volume":"71","author":"Hovav","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.prrv.2007.04.009_bib36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2249.2005.02668.x","article-title":"Vaccination of neonatal calves with Mycobacterium bovis BCG induces protection against intranasal challenge with virulent M. bovis","volume":"139","author":"Hope","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.prrv.2007.04.009_bib37","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/eji.200636128","article-title":"Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis","volume":"36","author":"Bennekov","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.prrv.2007.04.009_bib38","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1128\/IAI.71.11.6411-6419.2003","article-title":"Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination","volume":"71","author":"Buddle","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.prrv.2007.04.009_bib39","unstructured":"Hoft DF. Personal communication, 2006."},{"key":"10.1016\/j.prrv.2007.04.009_bib40","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.prrv.2007.04.009_bib41","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/nm1221","article-title":"Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis","volume":"11","author":"Kaufmann","year":"2005","journal-title":"Nature Med Rev"},{"key":"10.1016\/j.prrv.2007.04.009_bib42","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrmicro1419","article-title":"Advances in tuberculosis vaccine strategies","volume":"4","author":"Skeiky","year":"2006","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.prrv.2007.04.009_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1055\/s-0029-1206198","article-title":"Fortstzung \u00fcber ein Heilmittel gegen Tuberculose","volume":"17","author":"Koch","year":"1891","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.prrv.2007.04.009_bib44","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1128\/IAI.71.4.2192-2198.2003","article-title":"Pulmonary necrosis resulting from DNA vaccination against tuberculosis","volume":"71","author":"Taylor","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.prrv.2007.04.009_bib45","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm0896-893","article-title":"Immunogenicity and protective efficacy of a tuberculosis DNA vaccine","volume":"2","author":"Huygen","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.prrv.2007.04.009_bib46","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA)","volume":"99","author":"Stickl","year":"1974","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.prrv.2007.04.009_bib47","first-page":"253","article-title":"Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA","volume":"107","author":"Mahnel","year":"1994","journal-title":"Berl Munch Tierarztl Wochenschr"},{"key":"10.1016\/j.prrv.2007.04.009_bib48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0264-410X(03)00538-3","article-title":"Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals","volume":"22","author":"Cosma","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.prrv.2007.04.009_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/135965350501000212","article-title":"Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption","volume":"10","author":"Harrer","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.prrv.2007.04.009_bib50","unstructured":"McShane H. Personal communication, 2007."},{"key":"10.1016\/j.prrv.2007.04.009_bib51","series-title":"Phase one trial of modified vaccinia Ankara tuberculosis vaccine in adults in a high TB prevalence setting in South Africa Tuberculosis","author":"Hawkridge","year":"2006"},{"key":"10.1016\/j.prrv.2007.04.009_bib52","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1128\/IAI.71.4.1672-1679.2003","article-title":"A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis","volume":"71","author":"Horwitz","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.prrv.2007.04.009_bib53","doi-asserted-by":"crossref","first-page":"13853","DOI":"10.1073\/pnas.250480397","article-title":"Recombinant bacillus Calmette\u2013Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model","volume":"97","author":"Horwitz","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.prrv.2007.04.009_bib54","unstructured":"Hoft DF. Results of the 1st phase I trial of a recombinant BCG TB vaccine (rBCG30). Presented at US\u2013Japan Cooperative Medical Science Program; 40th Tuberculosis and Leprosy Research Conference, Seattle, Washington, 2005."},{"key":"10.1016\/j.prrv.2007.04.009_bib55","unstructured":"Aeras Global Tuberculosis Vaccine Foundation. Clinical Trial of a New TB Vaccine in the U.S. Begins. February 17, 2004. http:\/\/www.aeras.org\/news\/releases\/02172004.html."},{"key":"10.1016\/j.prrv.2007.04.009_bib56","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","article-title":"Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein","volume":"172","author":"Skeiky","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.prrv.2007.04.009_bib57","unstructured":"Ofori O. Personal communication, 2007."},{"key":"10.1016\/j.prrv.2007.04.009_bib58","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1128\/IAI.68.1.214-220.2000","article-title":"Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens","volume":"68","author":"Skjot","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.prrv.2007.04.009_bib59","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1128\/IAI.70.10.5446-5453.2002","article-title":"Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the ESAT-6 gene family","volume":"70","author":"Skjot","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.prrv.2007.04.009_bib60","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.prrv.2007.04.009_bib61","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/00002030-200405210-00019","article-title":"Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector","volume":"18","author":"Kostense","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.prrv.2007.04.009_bib62","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/31159","article-title":"Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence","volume":"393","author":"Cole","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.prrv.2007.04.009_bib63","unstructured":"Stop TB Partnership and World Health Organisation. Global Plan to stop TB 2006\u20132015. WHO\/HTM\/STB\/2006.35. Geneva: World Health Organization."},{"key":"10.1016\/j.prrv.2007.04.009_bib64","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/79631","article-title":"Is the development of a new tuberculosis vaccine possible?","volume":"6","author":"Kaufmann","year":"2000","journal-title":"Nature Med"},{"key":"10.1016\/j.prrv.2007.04.009_bib65","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0197-2456(94)90042-6","article-title":"Field trials of tuberculosis vaccines: how could we have done them better?","volume":"15","author":"Comstock","year":"1994","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.prrv.2007.04.009_bib66","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nm0307-299","article-title":"Changing funding patterns in tuberculosis","volume":"13","author":"Kaufmann","year":"2007","journal-title":"Nat Med"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054207000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054207000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T05:34:53Z","timestamp":1683869693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054207000401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S1526054207000401"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2007.04.009","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}